RxDoctor Payments Data

David Choma, MD

Nephrology · Gallatin, TNNPI 1447307251

Payments from drug & device makers

$802in general payments, 2019–2025

Across 28 payments — averaging $28.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$169
  • Bard Peripheral Vascular, Inc.$147
  • Otsuka America Pharmaceutical, Inc.$105
  • Novo Nordisk$80
  • Akebia Therapeutics Inc$74
  • Nxstage Medical, Inc.$66
  • plus $160 from 5 others

What the payments were for

  • Food & beverage$72991%
  • Education$739%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$802 in reported general payments places this provider in the 35th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$230,456
Medicare patients
518
Services billed
2,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin96$62,784
VelphoroSucroferric Oxyhydroxide23$49,987
KerendiaFinerenone59$36,603
FarxigaDapagliflozin Propanediol53$35,964
RenvelaSevelamer Carbonate14$24,666
RybelsusSemaglutide19$19,196
Sevelamer Carbonate83$9,758
Bumetanide43$2,721
Furosemide283$1,624
Calcium Acetate46$1,562
Calcitriol156$1,512
Potassium Chloride56$1,081
Losartan Potassium104$1,035
Torsemide30$1,020
Labetalol Hcl33$902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$17$62,78496 claims
Fresenius USA Marketing, Inc.Velphoro$23$49,98723 claims
BayerKerendia$23$36,60359 claims
AstraZenecaFarxiga$169$35,96453 claims
Novo NordiskRybelsus$80$19,19619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →